NasdaqGS:ARQTBiotechs
Why Arcutis Biotherapeutics (ARQT) Is Up 10.5% After FDA Filing to Expand ZORYVE for Children
Arcutis Biotherapeutics recently submitted a supplemental New Drug Application to the FDA seeking to expand the use of ZORYVE cream 0.3% for treating plaque psoriasis in children as young as 2 years old, supported by data from recent pediatric studies.
If approved, ZORYVE would be the first topical PDE4 inhibitor indicated for this age group, widening both its clinical and market reach.
We'll explore how the potential to make ZORYVE available for younger children could influence Arcutis...